#Novartis Pre-Earnings: Results from Q1 2020 Almost all other Novartis verticals including Oncology, Immunology and Neuroscience reported very strong revenue gains that were evident not only in the U.S. but also in Europe and Asia Pacific. #investing #stocks #earnings https://t.co/8bbI8d7w9e